Your browser doesn't support javascript.
loading
Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
Enriquez, Rocio; Homsi, Mahmoud; Ssekubugu, Robert; Nabukalu, Dorean; Zeebari, Zangin; Marrone, Gaetano; Gigante, Bruna; Chang, Larry W; Reynolds, Steven J; Nalugoda, Fred; Ekström, Anna Mia; Hagström, Hannes; Nordenstedt, Helena.
Affiliation
  • Enriquez R; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • Homsi M; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • Ssekubugu R; Rakai Health Sciences Program, Kalisizo, Uganda.
  • Nabukalu D; Rakai Health Sciences Program, Kalisizo, Uganda.
  • Zeebari Z; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • Marrone G; Jönköping International Business School, Jönköping University, Jönköping, Sweden.
  • Gigante B; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
  • Chang LW; Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
  • Reynolds SJ; Rakai Health Sciences Program, Kalisizo, Uganda.
  • Nalugoda F; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
  • Ekström AM; Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
  • Hagström H; Rakai Health Sciences Program, Kalisizo, Uganda.
  • Nordenstedt H; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Aliment Pharmacol Ther ; 59(9): 1111-1121, 2024 05.
Article in En | MEDLINE | ID: mdl-38459720
ABSTRACT

BACKGROUND:

Despite numerous risk factors and serious consequences, little is known about metabolic dysfunction-associated steatotic liver disease (MASLD) at population level in Africa.

AIM:

The aim of the study was to estimate the prevalence and risk factors of MASLD in people living with and without HIV in Uganda.

METHODS:

We collected data from 37 communities in South Central Uganda between May 2016 and May 2018. We estimated MASLD prevalence using the fatty liver index and advanced liver fibrosis using the dynamic aspartate-to-alanine aminotransferase ratio. We collected additional data on sociodemographics, HIV and cardiovascular disease (CVD) risk factors. We used multivariable logistic regression to determine the association between HIV, CVD risk factors and MASLD.

RESULTS:

We included 759 people with HIV and 704 HIV-negative participants aged 35-49. MASLD prevalence was 14% in women and 8% in men; advanced liver fibrosis prevalence was estimated to be <1%. MASLD prevalence was more common in women (15% vs. 13%) and men (9% vs. 6%) with HIV. Being female (odds ratio [OR] = 2.1; 95% confidence interval [CI] = 1.4-3.3) was associated with a higher odds of MASLD after adjustment for confounders; HIV infection was borderline associated with MASLD (OR = 1.4; 95% CI 1.0-2.0).

CONCLUSIONS:

In a relatively young cohort in Uganda, 14% of women and 8% of men had MASLD. There was an indication of an association between HIV and MASLD in multivariable analysis. These data are the first to describe the population-level burden of MASLD in sub-Saharan Africa using data from a population-based cohort.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / HIV Infections / Fatty Liver / Metabolic Diseases Limits: Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Sweden

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / HIV Infections / Fatty Liver / Metabolic Diseases Limits: Female / Humans / Male Country/Region as subject: Africa Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Sweden